EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia

Hae Won Jung iD, Chang-Yeon Kim, Seung-Pyo Hong iD, Han-Joon Bae, Ji Yong Choi, Jae Kean Ryu iD, Jin-Bae Lee, Kyoung-Hoon Lee, Kyoo-Rok Han, Dong-Heon Yang, Chang-Gyu Park iD, Gheol-Woong Yu und 16 weitere

The Journal of Clinical Hypertension · 2023

DOI: 10.1111/jch.14715 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Hypertension, 2023. Verfasst von Hae Won Jung und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Daegu Catholic University Medical Center, Daegu, Republic of Korea. Hauptthemen laut MEDLINE: Hypertension, Dyslipidemias, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The authors performed this study to investigate the efficacy and safety of a rosuvastatin (RSV)/amlodipine (AML) polypill compared with those of atorvastatin (ATV)/AML polypill. We included 259 patients from 21 institutions in Korea. Patients were randomly assigned to 1 of 3 treatment groups: RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, or ATV 20 mg /AML 5 mg. The primary endpoint was the efficacy of the RSV 10.20 mg/AML 5 mg via percentage changes in LDL‐C after 8 weeks of treatment, compared with the ATV 20 mg /AML 5 mg. There was a significant difference in the mean percentage change of LDL‐C at 8 weeks between the RSV 10 mg/AML 5 mg and the ATV 20 mg/AML 5 mg (full analysis set [FAS]: −7.08%, 95% CI: −11.79 to −2.38, p = .0034, per‐protocol analysis set [PPS]: −6.97%, 95% CI: −11.76 to −2.19, p = .0046). Also, there was a significant difference in the mean percentage change of LDL‐C at 8 weeks between the RSV 20 mg/AML 5 mg and the ATV 20 mg/AML 5 mg (FAS: −10.13%, 95% CI: −15.41 to −4.84, p = .0002, PPS: −10.96%, 95% CI: −15.98 to −5.93, p < .0001). There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg. In conclusion, while maintaining safety, RSV 10 mg/AML 5 mg and the RSV 20 mg/AML 5 mg more effectively reduced LDL‐C compared with the ATV 20 mg /AML 5 mg (Clinical trial: NCT03951207).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionDyslipidemiasLeukemia, Myeloid, AcuteHumansRosuvastatin CalciumAtorvastatinAmlodipineCholesterol, LDLDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

amlodipineatorvastatindyslipidemiahypertensionrosuvastatin

Substanzen

Rosuvastatin CalciumAtorvastatinAmlodipineCholesterol, LDL

Autor:innen und Institutionen

  • Department of Cardiology, Daegu Catholic University Medical Center, Daegu, Republic of Korea.
  • Department of Cardiology, Gachon University Gil Medical Center, Incheon, Republic of Korea.
  • Department of Cardiology, Kangdong Sacred Heart Hospital, Gangdong-gu, Republic of Korea.
  • Department of Cardiology, Kyungpook National University Hospital, Daegu, Republic of Korea.
  • Department of Cardiology, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Department of Cardiology, Korea University Anam Hospital, Seoul, Republic of Korea.

ORCID-Profile: Hae Won Jung, Seung-Pyo Hong, Jae Kean Ryu, Chang-Gyu Park, Moo-Yong Rhee

Zitieren

APA

Jung, H. W., Kim, C. Y., Hong, S. P., Bae, H. J., Choi, J. Y., Ryu, J. K., Lee, J. B., Lee, K. H., Han, K. R., Yang, D. H., Park, C. G., Yu, G. W., Rhee, M. Y., Park, S. J., Hyon, M. S., Shin, J. H., Hong, B. K., Jin, H. Y., Lee, S. Y., …, & Kim, K. S. (2023). Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14715

Vancouver

Jung HW, Kim CY, Hong SP, Bae HJ, Choi JY, Ryu JK, et al. Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. The Journal of Clinical Hypertension. 2023. doi:10.1111/jch.14715

BibTeX
@article{Jung2023,
  author = {Jung, Hae Won and Kim, Chang-Yeon and Hong, Seung-Pyo and Bae, Han-Joon and Choi, Ji Yong and Ryu, Jae Kean and Lee, Jin-Bae and Lee, Kyoung-Hoon and Han, Kyoo-Rok and Yang, Dong-Heon and Park, Chang-Gyu and Yu, Gheol-Woong and Rhee, Moo-Yong and Park, Sung-Ji and Hyon, Min-Su and Shin, Joon-Han and Hong, Bum-Kee and Jin, Han-Young and Lee, Sung-Yun and Seol, Sang-Hoon and Lee, Sang-Rok and Kim, Song-Yi and Lee, Kwang-Je and Cho, Eun-Joo and Nam, Chang-Wook and Park, Tae-Ho and Kim, Ung and Kim, Kee-Sik},
  title = {Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia},
  journal = {The Journal of Clinical Hypertension},
  year = {2023},
  doi = {10.1111/jch.14715}
}
Kostenlos starten →